Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Flament

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Cancer Research|July 19, 2005
BCR/ABL promotes dendritic cell-mediated natural killer cell activationMagali Terme, Christophe Borg, François Guilhot, et al.
Cell Cycle (Georgetown, Tex.)|January 5, 2011
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridaeMustapha Zoubir, Caroline Flament, Abdelaziz Gdoura, et al.
Journal of Leukocyte Biology|July 1, 2006
Dendritic cell derived-exosomes: biology and clinical implementationsNathalie Chaput, Caroline Flament, Sophie Viaud, et al.
Immunological Reviews|November 6, 2007
Ecto-calreticulin in immunogenic chemotherapyMichel Obeid, Antoine Tesniere, Theocharis Panaretakis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2004
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cellsFabrice André, Nathalie Chaput, Nöel E C Schartz, et al.
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylatePatricia Pautier, Clara Locher, Caroline Robert, et al.
Cancer Research|April 9, 2009
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patientsCédric Ménard, Jean-Yves Blay, Christophe Borg, et al.
Lancet (London, England)|July 31, 2002
Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 2004
IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 moleculesMagali Terme, Elena Tomasello, Koji Maruyama, et al.
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR<sup>+</sup> NK cell levels correlate with disease outcomeNathalie Chaput, Caroline Flament, Clara Locher, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Cancer Research|July 19, 2005
BCR/ABL promotes dendritic cell-mediated natural killer cell activationMagali Terme, Christophe Borg, François Guilhot, et al.
Cell Cycle (Georgetown, Tex.)|January 5, 2011
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridaeMustapha Zoubir, Caroline Flament, Abdelaziz Gdoura, et al.
Journal of Leukocyte Biology|July 1, 2006
Dendritic cell derived-exosomes: biology and clinical implementationsNathalie Chaput, Caroline Flament, Sophie Viaud, et al.
Immunological Reviews|November 6, 2007
Ecto-calreticulin in immunogenic chemotherapyMichel Obeid, Antoine Tesniere, Theocharis Panaretakis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2004
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cellsFabrice André, Nathalie Chaput, Nöel E C Schartz, et al.
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylatePatricia Pautier, Clara Locher, Caroline Robert, et al.
Cancer Research|April 9, 2009
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patientsCédric Ménard, Jean-Yves Blay, Christophe Borg, et al.
Lancet (London, England)|July 31, 2002
Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 2004
IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 moleculesMagali Terme, Elena Tomasello, Koji Maruyama, et al.
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR<sup>+</sup> NK cell levels correlate with disease outcomeNathalie Chaput, Caroline Flament, Clara Locher, et al.
Pageof 4